New and emerging developments in extensive-stage small cell lung cancer therapeutics.
New and emerging developments in extensive-stage small cell lung cancer therapeutics.
复制标题
DOI：
10.1097/cco.0000000000000264
复制
发表时间：
2016-03
影响因子：
3.4
通讯作者：
Lara PN Jr
中科院分区：
文献类型：
--
作者：
Parikh M;Riess J;Lara PN Jr
广泛期小细胞肺癌(SCLC)仍然是一种预后不佳的疾病，中位生存期约为8-10个月。尽管许多人试图开发有效的系统疗法，但在过去的几十年里，进展甚微。以铂为基础的联合化疗仍然是一线治疗的标准，并与高应答率有关，尽管时间较短。然而，最近在放射治疗的使用方面取得了进展，对小细胞肺癌的生物学也有了新的见解。在过去十年中，一些最引人注目的进步涉及到局部放射治疗的使用。随着基因组测序等新实验室技术的使用，合理定位药物开发的前景依然存在。循环肿瘤细胞的研究也可能为小细胞肺癌的生物学和进一步改进治疗提供见解。在过去的30年里，小细胞肺癌的系统治疗几乎没有什么变化，广泛期小细胞肺癌的最显着进展与放射治疗有关。预防性颅脑照射和胸部放射治疗的有效性重新引起了人们对调节DNA损伤或修复的治疗学的兴趣。基因组测序和免疫治疗的最新进展可能转化为小细胞肺癌的新治疗模式。
Extensive-stage small cell lung cancer (SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8–10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been advances in the use of radiation therapy, as well as new insights into the biology of SCLC recently. Some of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in extensive-stage small cell lung cancer relating to radiotherapy. The effectiveness of prophylactic cranial irradiation and thoracic radiation therapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.